Download Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020 Report

Immunotoxins are new generation chemotherapeutic agents innovated to include the specificity of monoclonal antibody and cytotoxicity of toxins extracted from plant or bacterial source. The targeting moiety carries the specificity of the antibody and is directed to the target where it either binds to the cell surface antigen, receptor or the ligand of the targeted disease. Cytotoxicity is mediated by the protein toxins, which maybe protein at times.

The cytotoxic part may comprise of any molecule which has the capability to induce cell death either by interfering with the cell machinery, modifying cell membrane, or by induction of apoptotic pathways. The cytotoxicity thus successfully delivered either to cytoplasm or the ribosomes of the target cell may be lethal to the cell.

During its ignition era, immunotoxins basically comprised of monoclonal antibodies (MAb) or growth factors chemically conjugated to protein toxins by the formation of the disulphide bonds. These molecules contained full length protein toxins are were not that cell specific. With progress in the research and technology, second generation immunotoxins made an entry. They were modulated in a way to remove the toxin mediated cell binding and spare the normal cells from cytotoxicity. The immunotoxins of this generation contained full length Immunoglobulin (IgG) bound to the toxic moiety.

The entry of third generation was marked by coming of recombinant technology which was targeted to remove the immunogenicity by shifting from murine origin immunoglobulins to humanized recombinant IgGs. The molecules of this generation thus formed consisted of fragments of variable domain (Fv) conjugated to IgG. Thus, created immunotoxins had excellent activity, specificity, better penetration and less immunogenicity.

Immunotoxins continue to be actively investigated as viable alternatives to conventional therapies for a variety of diseases. An array of different recombinant, antibody formats are now available for use in immunotoxins. While these design changes have improved the overall in vitro and preclinical in vivo efficacy of immunotoxins, increased potency does not address either of the two major concerns for drugs of this type: immunogenicity and toxicity.

In the past few decades, a wide variety of immunotoxins have been tested against multiple malignancies in cell culture, in animal models, and in patients. The most useful of these agents appear to be the relatively small recombinant fusion toxins that contain either growth factor or Fv fragments as ligands. The most sensitive diseases appear to be hematologic malignancies. Future development will need to address combinations of immunotoxins with other anticancer therapies in order to overcome problems of tumor penetration, toxicity, and immunogenicity.

After many years of pre-clinical development, there has been a recent burst in the number of clinical trials using antibodies or antibody fragments to target potent cytotoxic molecules to cancer cells. Several of these trials have shown impressive clinical responses indicating that we are at the beginning of a new and exciting phase of cancer treatment. Additional studies are now required to define the optimal dose, schedule, and combinations for specific malignancies. Also several problems have been identified. One of these is immunogenicity, which may be solved by removing B and T cell epitopes. Another is likely to be drug and toxin resistance. Never the less we expect this new approach is likely to have a major impact in cancer treatment.

“Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020” Report Highlights:
Introduction to Immunotoxins
Cancer Immunotoxins Therapy Analysis
Advantages of Immunotoxins upon other Anticancerous Drugs
Applications of Immunotoxins to Multiple Cancer Therapies
Global Cancer Immunotoxins Market Future Prospects
Global Cancer Immunotoxins Clinical Pipeline by Company, Indication & Phase
Global Cancer Immunotoxins Clinical Pipeline: 52 Cancer Immunotoxins
Majority Cancer Immunotoxins in Preclinical Phase: 21 Drugs

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-Global-Cancer-Immunotoxins-Market-&-Clinical-Pipeline-Insight-2020.php

1. Introduction to Immunotoxins

2. Immunotoxins: The Three Generations & Advancements

3. Sources of Toxins
3.1 Plant Toxins
3.2 Bacterial Toxins

4. Production of Immunotoxins

5. Types of Immunotoxins
5.1 Anthrax Based Toxins
5.2 Diphtheria Toxin (DT) & DT Derivatives
5.3 Pseudomonas Exotoxin (PE) & PE Derivatives
5.4 Ribosome Inactivating Proteins Based Immunotoxins
5.4.1 Ricin
5.4.2 Saporin based Immunotoxins
5.4.3 Recombinant Constructs of RIP I Toxins
5.5 Ribonucleases based Immunotoxins
5.6 Proapoptotic Proteins as Targeted Immunotoxins

6. Cancer Immunotoxins Therapy Analysis
6.1 Immunotoxins for Hematologic Malignancies
6.1.1 Denileukin Diftitox (ONTAK, DAB389IL-2)
6.1.2 LMB-2 (anti-Tac[Fv]-PE38)
6.1.3 Moxetumomab Pasudotox
6.1.4 A-dmDT390-bisFv (UCHT1)
6.1.5 DT2219ARL
6.1.6 HuM195-Gelonin
6.2 Immunotoxins for Solid Tumors
6.2.1 SS1P
6.2.2 RG7787
6.2.3 Oportuzumab Monatox
6.2.4 VB6-845
6.2.5 D2C7-(scdsFv)-PE38KDEL

7. Advantages of Immunotoxins upon other Anticancerous Drugs

8. Applications of Immunotoxins
8.1 Immunotoxins against Solid Tumors
8.1.1 Immunotoxin against Colon Carcinoma
8.1.2 Immunotoxin against Breast Cancer & Sarcoma
8.1.3 Immunotoxin against Glioma & Head & Neck Squamous Cell Carcinoma
8.1.4 Immunotoxin against Prostate & Lung Cancer
8.2 Immunotoxins against Leukemias
8.3 Immunotoxin Complementation of HAART to Deplete Persisting HIV-Infected Cell Reservoirs

9. Global Cancer Immunotoxins Market Outlook
9.1 Current Market Scenario
9.2 Cancer Immunotoxins Clinical Pipeline Overview

10. Global Cancer Immunotoxins Market Dynamics
10.1 Favorable Parameters
10.1.1 Large Segment of Patient Still Devoid of Appropriate Medication
10.1.2 Cancer: A Severe Pathological Condition
10.1.3 Unmet Requirement of Completely Curative Agents
10.1.4 Unwanted Effects of the Existing Drugs
10.2 Commercialization Challenges
10.2.1 Stern Regulatory Guidelines: A Major Hurdle
10.2.2 Never Ending Phase of Research & Development
10.2.3 Conduction of Clinical Trials
10.2.4 Funding Research & Development: A Super Costly Affair
10.2.5 Immunogenicity of Immunotoxins

11. Global Cancer Immunotoxins Market Future Prospects

12. Global Cancer Immunotoxins Clinical Pipeline by Company, Indication & Phase
12.1 Research
12.2 Preclinical
12.3 Phase-I
12.4 Phase-I/II
12.5 Phase-II
12.6 Phase-II/III
12.7 Phase-III

13. Discontinued & No Development in Cancer Immunotoxins Clinical Pipeline by Company, Indication & Phase
13.1 No Development Reported
13.2 Discontinued
13.3 Suspended

14. Competitive Landscape
14.1 AbbVie
14.2 AbGenomics
14.3 Agensys
14.4 Ambrx
14.5 Amgen
14.6 AREVA Med
14.7 Bayer HealthCare
14.8 Biotest
14.9 Celldex Therapeutics
14.10 CuraGen Corporation
14.11 Genentech
14.12 Genmab
14.13 Heidelberg Pharma
14.14 ImmunoGen
14.15 Neurocrine Biosciences
14.16 Research Corporation Technologies
14.17 Sanofi
14.18 Seattle Genetics
14.19 Sorrento Therapeutics
14.20 Spirogen

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Kuick Research
New Delhi - 110001
India
+91-11-47067990

This release was published on openPR.